Ferrihydrite : Fundamentals of a Natural Nanomaterial. The overarching goal of this project is to obtain the depth of knowledge necessary to achieve specific size, composition and morphology control in the crystallization of nanometer-sized iron oxides. The project focusses on the structural characteristics of the oxy-hydroxide phase ferrihydrite, which is a key intermediate in the formation of other iron oxides. The project will employ characterization techniques such as small-angle scattering ....Ferrihydrite : Fundamentals of a Natural Nanomaterial. The overarching goal of this project is to obtain the depth of knowledge necessary to achieve specific size, composition and morphology control in the crystallization of nanometer-sized iron oxides. The project focusses on the structural characteristics of the oxy-hydroxide phase ferrihydrite, which is a key intermediate in the formation of other iron oxides. The project will employ characterization techniques such as small-angle scattering, high resolution TEM, electron nanodiffraction and magnetic energy barrier distribution measurements to study crystallization processes of the iron oxy-hydroxide ferrihydrite, both in vivo and in vitro. The knowledge gained from the biological realm will allow us to devise new laboratory techniques for the preparation of nanoparticles, and provide important information about iron biomineralization to advance the treatment of iron overload diseases.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100236
Funder
Australian Research Council
Funding Amount
$180,000.00
Summary
Facilities for spectroscopy and diffraction at high pressures. The provision of infrastructure for the study of novel materials under high pressures will enhance Australia's capability in creating new materials and in creating new devices that meet needs in communication, environment and medicine applications. The new facility will enable researchers to understand the response of structures to extreme pressures and will exploit the unique capabilities of the synchrotron light.
Tuneable monodispersed nanoparticles and nanoparticle superstructures. Integrating spinning disc processing (SDP), which is new to Australia, with advances in magnetic properties of nanoparticles will have wide ranging applications in nanotechnology. The cutting edge research will foster collaboration with industry, and lead to new industries in memory device technology, nano-medicine, and catalysis, through exploiting commercial opportunities. Continuous flow SDP technology in industry has a s ....Tuneable monodispersed nanoparticles and nanoparticle superstructures. Integrating spinning disc processing (SDP), which is new to Australia, with advances in magnetic properties of nanoparticles will have wide ranging applications in nanotechnology. The cutting edge research will foster collaboration with industry, and lead to new industries in memory device technology, nano-medicine, and catalysis, through exploiting commercial opportunities. Continuous flow SDP technology in industry has a small footprint and low capital cost outlay. The project will provide excellent research training in a range of scientific skills and in professional development, and will involve overseas PhD exchange programs. The exciting research incorporating nano-toxicology will enhance public opinion towards nanotechnology.Read moreRead less
Gold-based mitochondria targeted chemotherapeutics: mechanistic studies probing interactions with thiol and selenol containing proteins. Cancer affects one in four Australians and prostate cancer is the most commonly diagnosed and second leading cause of male cancer deaths, for which there is currently no effective treatment. Current chemotherapeutics must overcome drug resistance and lack of selectivity between tumour and normal cells. To circumvent these problems we are investigating gold-base ....Gold-based mitochondria targeted chemotherapeutics: mechanistic studies probing interactions with thiol and selenol containing proteins. Cancer affects one in four Australians and prostate cancer is the most commonly diagnosed and second leading cause of male cancer deaths, for which there is currently no effective treatment. Current chemotherapeutics must overcome drug resistance and lack of selectivity between tumour and normal cells. To circumvent these problems we are investigating gold-based compounds, which act by a novel mechanism. The research will lead to new strategies in the design of improved anticancer drugs, an important Australian research priority that will promote and maintain good health. Other benefits arise from training PhD students with interdisciplinary skills for Australian biotechnology industries.Read moreRead less
Structural studies of titanyl and zirconyl sulfate hydrates. This project aims to provide knowledge that will inform the development of new methods of extraction and refining of titanium from ilmenite ores. In addition the knowledge gained in this research will aid the design and synthesis advanced ceramics and nanocomposites, and will provide the fundamental understanding of material structures that are required to adequately control the formation of such materials.
NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these ne ....NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.Read moreRead less
DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the dr ....DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration betwe ....Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
NMR studies on DNA interactions of polynuclear platinum. BBR3464 is representative of a class of structurally unique platinum anticancer drugs, and is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow in detail the stepwise formation of DNA adducts. Further extension to reactions of polynuclear platinum complexes with sulfur ....NMR studies on DNA interactions of polynuclear platinum. BBR3464 is representative of a class of structurally unique platinum anticancer drugs, and is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow in detail the stepwise formation of DNA adducts. Further extension to reactions of polynuclear platinum complexes with sulfur nucleophiles will aid in understanding their metabolism and toxicity. The results of this work will aid in the selection of back-up clinical candidates and the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less